Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2015, No. 2


Herman LH, Alanís-Garza EJ, Estrada PMF, Mureyko LL, Alarcón TDA, Ixtepan TL
Nutrición que previene el estrés oxidativo causante del Alzheimer. Prevención del Alzheimer
Gac Med Mex 2015; 151 (2)

Idioma: Español
Referencias bibliográficas: 57
Paginas: 245-251
Archivo PDF: 117.77 Kb.


Texto completo




RESUMEN

La principal causa de demencia en el mundo es la enfermedad de Alzheimer (EA), que suele encontrarse después de los 65 años de edad y es de carácter progresivo. Esperando un rápido aumento de su incidencia y sabiendo que no tiene cura, resulta recomendable buscar la forma de prevenirla. Los cambios en la dieta debido a la globalización podrían explicar el aumento de la incidencia de esta enfermedad en lugares como Japón y los países mediterráneos, que contaban con un menor índice de presentación. Existe una correlación directa entre la progresión de la enfermedad y el alto consumo de alcohol, grasas, carnes rojas, que conllevan obesidad y un aumento de los niveles séricos de colesterol por la alta ingesta de grasas saturadas. Para prevenir esta enfermedad se proponen dietas ricas en polifenoles, que son potentes antioxidantes, grasas mono y poliinsaturadas, así como consumir mayores cantidades de grasa derivada del pescado, grasas vegetales y frutas con bajo índice glucémico, y un moderado consumo de vino tinto. A través de una dieta rica en antioxidantes se puede prevenir la progresión hacia la demencia y la EA. Este artículo enfatiza los alimentos y otros compuestos que han demostrado tener la capacidad de disminuir el riesgo de padecer esta enfermedad crónica degenerativa.


Palabras clave: Alzheimer, Demencia, Dieta, Antioxidante, Prevención.


REFERENCIAS

  1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Demnt. 2013;9(1):63-75.e2.

  2. Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer’s disease. Pharmaceuticals (Basel). 2013;6(10):1304-21.

  3. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-83.

  4. Wortmann M. Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012;4(5):40.

  5. Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ε4,and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483-92.

  6. Gandy S, DeKosky S. Toward the treatment and prevention of Alzheimer’s disease: rational strategies and recent progress. Annu Rev Med. 2013;64:367-83.

  7. Chin AL, Negash S, Hamilton R. Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(3):187-95.

  8. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-83.

  9. Cipriani G, Dolciotti C, Picchi L, Bonuccelli U. Alzheimer and his disease: a brief history. Neurol Sci. 2011;32(2):275-9.

  10. Singhal AK, Naithani V, Om Prakash Bangar. Medicinal plants with a potential to treat Alzheimer and associated symptoms. IJNPND. 2012;2:84-91.

  11. Iqbal K, Flory M, Soininen H. Clinical symptoms and symptom signatures of Alzheimer’s disease subgroups. J Alzheimers Dis. 2013;37(3):475-81.

  12. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology. 1997; 48(1):139-47.

  13. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16.

  14. Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281(1):46-62.

  15. Medina M, Avila J. New insights into the role of glycogen synthase kinase-3 in Alzheimer’s disease. Expert Opin Ther Targets. 2014;18(1): 69-77.

  16. Goutagny R, Krantic S. Hippocampal Oscillatory Activity in Alzheimer’s Disease: Toward the Identification of Early Biomarkers? Aging Dis. 2013;4(3):134-40.

  17. Brayda-Bruno L, Mons N, Yee BK, et al. Partial loss in septo-hippocampal cholinergic neurons alters memory-dependent measures of brain connectivity without overt memory deficits. Neurobiol Dis. 2013;54: 372-81.

  18. La Joie R, Perrotin A, de La Sayette V, et al. Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer’s disease and semantic dementia. Neuroimage (Amst). 2013;3:155-62.

  19. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-42.

  20. Zhang X, Li H, Mao Y, et al. An over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technology. PLoS One. 2013;8(11):e75493.

  21. Tyagi E, Fiorelli T, Norden M, Padmanabhan J. Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer’s Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation. Int J Alzheimers Dis. 2013;2013:606083.

  22. Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis. 2013;33 Suppl 1:S67-78.

  23. Parajuli B, Sonobe Y, Horiuchi H, Takeuchi H, Mizuno T, Suzumura A. Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer’s disease. Cell Death Dis. 2013;4:e975.

  24. Schrag M, Mueller C, Zabel M, et al. Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis. 2013;59:100-10.

  25. Guerra-Araiza C, Álvarez-Mejía AL, Sánchez-Torres S, et al. Effect of natural exogenous antioxidants on aging and on neurodegenerative diseases. Free Radic Res. 2013;47(6-7):451-62.

  26. Cimini A, Gentile R, D’Angelo B, et al. Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer’s disease model by modulating BDNF signaling pathway. J Cell Biochem. 2013;114(10): 2209-20.

  27. Hou CW, Lin YT, Chen YL, et al. Neuroprotective effects of carnosic acid on neuronal cells under ischemic and hypoxic stress. Nutr Neurosci. 2012. [Epub ahead of print]

  28. Quitschke WW, Steinhauff N, Rooney J. The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection. Alzheimers Res Ther. 2013;5(2):16.

  29. Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY. Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol. 2012;51(4):515-25.

  30. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:1-11.

  31. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer’s disease. Int J Mol Sci. 2013;14(7):14575-93.

  32. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1(3):280-91.

  33. Bernal-Mondragón C, Rivas-Arancibia S, Kendrick KM, Guevara-Guzmán R. Estradiol prevents olfactory dysfunction induced by A-beta 25-- 35 injection in hippocampus. BMC Neurosci. 2013;14:104.

  34. Balsamo S, Willardson JM, Frederico Sde S, et al. Effectiveness of exercise on cognitive impairment and Alzheimer’s disease. Int J Gen Med. 2013;6:387-91.

  35. Ashare RL, Karlawish JH, Wileyto EP, Pinto A, Lerman C. APOE ε4, an Alzheimer’s disease susceptibility allele, and smoking cessation. Pharmacogenomics J. 2013;13(6):538-43.

  36. Hu N, Yu JT, Tan L, Wang YL, Sun L, Tan L. Nutrition and the risk of Alzheimer’s disease. Biomed Res Int. 2013;2013:1-12.

  37. Dhungana H, Rolova T, Savchenko E, et al. Western-type diet modulates inflammatory responses and impairs functional outcome following permanent middle cerebral artery occlusion in aged mice expressing the human apolipoprotein E4 allele. J Neuroinflammation. 2013;10:102.

  38. Dodge HH, Buracchio TJ, Fisher GG, et al. Trends in the prevalence of dementia in Japan. Int J Alzheimers Dis. 2012;2012:956354.

  39. Pallauf K, Giller K, Huebbe P, Rimbach G. Nutrition and healthy ageing: calorie restriction or polyphenol-rich «MediterrAsian» diet? Oxid Med Cell Longev. 2013;2013:707421.

  40. Shinto L, Quinn J, Montine T, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis. 2014;38(1):111-20.

  41. Hu N, Yu JT, Tan L, Wang YL, Sun L, Tan L. Nutrition and the risk of Alzheimer’s disease. Biomed Res Int. 2013;2013:524820.

  42. Hjorth E, Zhu M, Toro VC, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013;35(4):697-713.

  43. Lim HJ, Shim SB, Jee SW, et al. Green tea catechin leads to global improvement among Alzheimer’s disease-related phenotypes in NSE/ hAPP-C105 Tg mice. J Nutr Biochem. 2013;24(7):1302-13.

  44. Pasinetti GM. Novel role of red wine-derived polyphenols in the prevention of Alzheimer’s disease dementia and brain pathology: experimental approaches and clinical implications. Planta Med. 2012;78(15):1614-9.

  45. Bhullar KS, Rupasinghe HP. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev. 2013;2013:894718.

  46. Azad N, Rasoolijazi H, Taghi-Joghataie M, Soleimani S. Neuroprotective Effects of Carnosic Acid in an Experimental Model of Alzheimer’s Disease in Rats. Cell J. 2011;13(1):39-44.

  47. Meng P, Yoshida H, Matsumiya T, et al. Carnosic acid suppresses the production of amyloid-β 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells. Neurosci Res. 2013;75(2):94-102.

  48. Hyung SJ, DeToma AS, Brender JR, et al. Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc Natl Acad Sci U S A. 2013;110(10):3743-8.

  49. Lee YJ, Choi DY, Yun YP, Han SB, Oh KW, Hong JT. Epigallocatechin- 3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J Nutr Biochem. 2013;24(1):298-310.

  50. Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL. Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One. 2011;6(12):1-9.

  51. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci. 2014;39(1):6-21.

  52. Cižas P, Jekabson˙e A, Borutait˙e V, Morkˉunien˙e R. Prevention of amyloid- beta oligomer-induced neuronal death by EGTA, estradiol, and endocytosis inhibitor. Medicina (Kaunas). 2011;47(2):107-12.

  53. Barron A, Pike C. Sex hormones, aging, and Alzheimer’s disease. Front Biosci. 2012;4:976-97.

  54. Grimm A, Lim YA, Mensah-Nyagan AG, Götz J, Eckert A. Alzheimer’s disease, oestrogen and mitochondria: an ambiguous relationship. Mol Neurobiol. 2012;46(1):151-60.

  55. Seyedreza P, Alireza MN, Seyedebrahim H. Role of testosterone in memory impairment of Alzheimer disease induced by Streptozotocin in male rats. Daru. 2012;20(1):98.

  56. Butchart J, Birch B, Bassily R, Wolfe L, Holmes C. Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27(2):153-6.

  57. Rosario ER, Carroll JC, Pike CJ. Evaluation of the effects of testosterone and luteinizing hormone on regulation of β-amyloid in male 3xTg-AD mice. Brain Res. 2012;1466:137-45.



>Revistas >Gaceta Médica de México >Año2015, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019